<!doctype html><html lang=zh-tw><head><meta charset=utf-8><meta name=description content="METABOLIC EMERGENCIES Tumor lysis Syndrome and Hypercalcemia æ—å”éœ† TUMOR Lysis syndrome Definition TLS is an oncologic emergency caused by electrolyte abnormalities"><meta property="og:title" content><meta property="og:description" content><meta property="og:type" content="website"><meta property="og:url" content><meta property="og:image" content="https://og-ph6wrfvo1-htlin222.vercel.app/api/blog?templateTitle="><title>èœ¥èœ´èŠ±åœ’ğŸ¦ğŸŒ±ğŸª´ğŸŒ²</title><meta name=viewport content="width=device-width,initial-scale=1"><link rel=alternate type=application/rss+xml href=https://www.physician.tw//feed.xml title><link rel="shortcut icon" type=image/png href=https://www.physician.tw//icon.png><link href=https://www.physician.tw/styles.720e2c4835986a3891d6eef3a55faa22.min.css rel=stylesheet><link href=https://www.physician.tw/styles/_light_syntax.86a48a52faebeaaf42158b72922b1c90.min.css rel=stylesheet id=theme-link><script src=https://www.physician.tw/js/darkmode.dfadb738e747a87e78c7144d7267f1bc.min.js></script>
<script src=https://www.physician.tw/js/util.6f22941e242efae60fd84e7c32e874fa.min.js></script>
<link rel=preload href=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.css as=style onload='this.onload=null,this.rel="stylesheet"' integrity=sha384-R4558gYOUz8mP9YWpZJjofhk+zx0AS11p36HnD2ZKj/6JR5z27gSSULCNHIRReVs crossorigin=anonymous><script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.js integrity=sha384-z1fJDqw8ZApjGO3/unPWUPsIymfsJmyrDVWC8Tv/a1HeOtGmkwNd/7xUS0Xcnvsx crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/contrib/auto-render.min.js integrity=sha384-+XBljXPPiv+OzfbB3cVmLHf4hdUFHlWNZN5spNQ7rmHTXpd7WvJum6fIACpNNfIR crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.16.2/dist/contrib/copy-tex.min.js integrity=sha384-ww/583aHhxWkz5DEVn6OKtNiIaLi2iBRNZXfJRiY1Ai7tnJ9UXpEsyvOITVpTl4A crossorigin=anonymous></script>
<script async src=https://unpkg.com/@floating-ui/core@0.7.3></script>
<script async src=https://unpkg.com/@floating-ui/dom@0.5.4></script>
<script async src=https://www.physician.tw/js/popover.f03552ccb84d99ca615d1cfb9abde59e.min.js></script>
<script defer src=https://www.physician.tw/js/code-title.ce4a43f09239a9efb48fee342e8ef2df.min.js></script>
<script defer src=https://www.physician.tw/js/clipboard.2913da76d3cb21c5deaa4bae7da38c9f.min.js></script>
<script defer src=https://www.physician.tw/js/callouts.7723cac461d613d118ee8bb8216b9838.min.js></script>
<script>const SEARCH_ENABLED=!1,LATEX_ENABLED=!0,PRODUCTION=!0,BASE_URL="https://www.physician.tw/",fetchData=Promise.all([fetch("https://www.physician.tw/indices/linkIndex.ba063fb2c262e32806125420a04897fb.min.json").then(e=>e.json()).then(e=>({index:e.index,links:e.links})),fetch("https://www.physician.tw/indices/contentIndex.b3b05d7aa4a3b117fe66eb314e8eecf6.min.json").then(e=>e.json())]).then(([{index:e,links:t},n])=>({index:e,links:t,content:n})),render=()=>{const e=new URL(BASE_URL),t=e.pathname,n=window.location.pathname,s=t==n;addCopyButtons(),addTitleToCodeBlocks(),addCollapsibleCallouts(),initPopover("https://www.physician.tw",!0);const o=document.getElementById("footer");if(o){const e=document.getElementById("graph-container");if(!e)return requestAnimationFrame(render);e.textContent="";const t=s&&!1;drawGraph("https://www.physician.tw",t,[{"/moc":"#4388cc"}],t?{centerForce:1,depth:-1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.5,linkDistance:1,opacityScale:3,repelForce:1,scale:1.4}:{centerForce:1,depth:1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.6,linkDistance:1,opacityScale:3,repelForce:2,scale:1.2})}},init=(e=document)=>{addCopyButtons(),addTitleToCodeBlocks(),renderMathInElement(e.body,{delimiters:[{left:"$$",right:"$$",display:!0},{left:"$",right:"$",display:!1}],macros:{'â€™':"'"},throwOnError:!1})}</script><script type=module>
    import { attachSPARouting } from "https:\/\/www.physician.tw\/js\/router.9d4974281069e9ebb189f642ae1e3ca2.min.js"
    attachSPARouting(init, render)
  </script></head><body><div id=search-container><div id=search-space><input autocomplete=off id=search-bar name=search type=text aria-label=æœå°‹ placeholder="è«‹è¼¸å…¥åƒæ˜¯ï¼šhypertension ä¹‹é¡çš„ä¾†çœ‹æ²’æœ‰æ²’ä»€éº¼æœ‰è¶£çš„ğŸ³"><div id=results-container></div></div></div><script src=https://cdn.jsdelivr.net/npm/flexsearch@0.7.21/dist/flexsearch.bundle.js integrity="sha256-i3A0NZGkhsKjVMzFxv3ksk0DZh3aXqu0l49Bbh0MdjE=" crossorigin=anonymous defer></script>
<script defer src=https://www.physician.tw/js/full-text-search.e6e2e0c213187ca0c703d6e2c7a77fcd.min.js></script><div class=singlePage><header><h1 id=page-title><a href=https://www.physician.tw/>èœ¥èœ´èŠ±åœ’ğŸ¦ğŸŒ±ğŸª´ğŸŒ²</a></h1><div class=spacer></div><div id=search-icon><p>æœå°‹</p><svg tabindex="0" aria-labelledby="title desc" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 19.9 19.7"><title id="title">æœå°‹åœ–ç¤º</title><desc id="desc">æ‰“é–‹æœå°‹åœ–æ¨™</desc><g class="search-path" fill="none"><path stroke-linecap="square" d="M18.5 18.3l-5.4-5.4"/><circle cx="8" cy="8" r="7"/></g></svg></div><div class=darkmode><input class=toggle id=darkmode-toggle type=checkbox tabindex=-1>
<label id=toggle-label-light for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="dayIcon" viewBox="0 0 35 35" style="enable-background:new 0 0 35 35"><title>æ˜äº®æ¨¡å¼</title><path d="M6 17.5C6 16.672 5.328 16 4.5 16h-3C.672 16 0 16.672.0 17.5S.672 19 1.5 19h3C5.328 19 6 18.328 6 17.5zM7.5 26c-.414.0-.789.168-1.061.439l-2 2C4.168 28.711 4 29.086 4 29.5 4 30.328 4.671 31 5.5 31c.414.0.789-.168 1.06-.44l2-2C8.832 28.289 9 27.914 9 27.5 9 26.672 8.329 26 7.5 26zm10-20C18.329 6 19 5.328 19 4.5v-3C19 .672 18.329.0 17.5.0S16 .672 16 1.5v3C16 5.328 16.671 6 17.5 6zm10 3c.414.0.789-.168 1.06-.439l2-2C30.832 6.289 31 5.914 31 5.5 31 4.672 30.329 4 29.5 4c-.414.0-.789.168-1.061.44l-2 2C26.168 6.711 26 7.086 26 7.5 26 8.328 26.671 9 27.5 9zM6.439 8.561C6.711 8.832 7.086 9 7.5 9 8.328 9 9 8.328 9 7.5c0-.414-.168-.789-.439-1.061l-2-2C6.289 4.168 5.914 4 5.5 4 4.672 4 4 4.672 4 5.5c0 .414.168.789.439 1.06l2 2.001zM33.5 16h-3c-.828.0-1.5.672-1.5 1.5s.672 1.5 1.5 1.5h3c.828.0 1.5-.672 1.5-1.5S34.328 16 33.5 16zM28.561 26.439C28.289 26.168 27.914 26 27.5 26c-.828.0-1.5.672-1.5 1.5.0.414.168.789.439 1.06l2 2C28.711 30.832 29.086 31 29.5 31c.828.0 1.5-.672 1.5-1.5.0-.414-.168-.789-.439-1.061l-2-2zM17.5 29c-.829.0-1.5.672-1.5 1.5v3c0 .828.671 1.5 1.5 1.5s1.5-.672 1.5-1.5v-3C19 29.672 18.329 29 17.5 29zm0-22C11.71 7 7 11.71 7 17.5S11.71 28 17.5 28 28 23.29 28 17.5 23.29 7 17.5 7zm0 18c-4.136.0-7.5-3.364-7.5-7.5s3.364-7.5 7.5-7.5 7.5 3.364 7.5 7.5S21.636 25 17.5 25z"/></svg></label><label id=toggle-label-dark for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="nightIcon" viewBox="0 0 100 100" style="enable-background='new 0 0 100 100'"><title>é»‘æš—æ¨¡å¼</title><path d="M96.76 66.458c-.853-.852-2.15-1.064-3.23-.534-6.063 2.991-12.858 4.571-19.655 4.571C62.022 70.495 50.88 65.88 42.5 57.5 29.043 44.043 25.658 23.536 34.076 6.47c.532-1.08.318-2.379-.534-3.23-.851-.852-2.15-1.064-3.23-.534-4.918 2.427-9.375 5.619-13.246 9.491-9.447 9.447-14.65 22.008-14.65 35.369.0 13.36 5.203 25.921 14.65 35.368s22.008 14.65 35.368 14.65c13.361.0 25.921-5.203 35.369-14.65 3.872-3.871 7.064-8.328 9.491-13.246C97.826 68.608 97.611 67.309 96.76 66.458z"/></svg></label></div></header><article><p class=meta>æœ€å¾Œæ›´æ–°æ–¼
Aug 28, 2023
<a href=https://github.com/htlin222/garden/tree/hugo/content/slides/TLS_hyperCa.md rel=noopener>ğŸªš ç·¨è¼¯åŸå§‹æ–‡ä»¶</a></p><ul class=tags></ul><aside class=mainTOC><details><summary>ğŸ“’ç›®éŒ„</summary><nav id=TableOfContents><ol><li><ol><li><a href=#tumor-lysis-syndrome-and-hypercalcemia>Tumor lysis Syndrome and Hypercalcemia</a></li></ol></li></ol><ol><li><a href=#definition>Definition</a></li><li><a href=#4-key-electrolyte-abnormalities-2-to-excessive-tumorcell-lysis>4 key electrolyte abnormalities 2Â° to excessive tumor/cell lysis:</a></li><li><a href=#presentation>Presentation</a></li><li><a href=#cairobishop-classification-system-for-tls-br-j-haematol-20041273>Cairoâ€“Bishop Classification System for TLS (Br J Haematol 2004;127:3)</a><ol><li><a href=#lab-tls>Lab TLS:</a></li><li><a href=#clinical-tls-1-lab-tls-marker-plus-1-clinical-abnormalities>Clinical TLS: â‰¥1 lab TLS marker plus â‰¥1 clinical abnormalities</a></li></ol></li><li><a href=#a-severity-grading-system-for-tls>A severity grading system for TLS</a></li><li><a href=#common-malignancies-associated-with-a-high-risk-of-developing-tls-in-adult-patients>Common Malignancies Associated with a High Risk of Developing TLS in Adult Patients</a></li><li><a href=#certain-targeted-therapies-have-a-higher-risk-of-tls-in-cll-or-indolent-nhl>Certain targeted therapies have a higher risk of TLS in CLL or indolent NHL:</a><ol><li><a href=#venetoclax-especially-w>Venetoclax, especially w/</a></li><li><a href=#obinutuzumab-no-large-tls-risk-w-follicular-lymphoma>Obinutuzumab, no large TLS risk w/ follicular lymphoma</a></li></ol></li><li><a href=#risk-factors>Risk Factors</a><ol><li><a href=#disease-characteristics-aw-tls-risk>disease characteristics a/w TLS risk:</a></li><li><a href=#pt-characteristics-aw-tls-risk>Pt characteristics a/w TLS risk:</a></li></ol></li><li><a href=#monitoring>Monitoring</a><ol><li><a href=#telemetry>Telemetry</a></li><li><a href=#labs>Labs:</a></li><li><a href=#high-risk-pts>High-risk pts</a></li><li><a href=#intermediate--or-low-risk-pts>Intermediate- or low-risk pts</a></li></ol></li><li><a href=#prophylaxis>Prophylaxis</a></li></ol><ol><li><a href=#hyperkalemia>Hyperkalemia:</a><ol><li><a href=#clinical-ss>Clinical S/S:</a></li><li><a href=#tx>Tx:</a></li></ol></li><li><a href=#hyperphosphatemia>Hyperphosphatemia:</a><ol><li></li></ol></li><li><a href=#hypocalcemia>Hypocalcemia:</a><ol><li><a href=#clinical-ss-2>Clinical s/s:</a></li></ol></li><li><a href=#hyperuricemia>Hyperuricemia:</a><ol><li></li></ol></li><li><a href=#allopurinol-vs-rasburicase>Allopurinol vs. Rasburicase</a></li></ol><ol><li><a href=#hypercalcemia-overview>Hypercalcemia: Overview</a><ol><li><a href=#epidemiology>Epidemiology:</a></li><li><a href=#definition-1>Definition:</a></li><li><a href=#ä¸€èˆ¬æƒ…æ³éƒ½æ˜¯æŠ½caalb>ä¸€èˆ¬æƒ…æ³éƒ½æ˜¯æŠ½Ca+Alb:</a></li><li><a href=#freecaä¸€èˆ¬ä¾†èªªæ˜¯ä¸€èˆ¬caçš„40-50>FreeCaï¼Œä¸€èˆ¬ä¾†èªªæ˜¯ä¸€èˆ¬Caçš„40-50%</a></li><li><a href=#tldr>TLDR</a></li><li><a href=#pathogenesis>Pathogenesis:</a></li><li><a href=#symptoms>Symptoms:</a></li></ol></li><li><a href=#workup>Workup:</a><ol><li><a href=#hp>H/P:</a></li><li><a href=#labs-1>Labs:</a></li></ol></li><li><a href=#hypercalcemia-humoral-mechanisms>Hypercalcemia: Humoral Mechanisms</a><ol><li><a href=#epidemiology-1>Epidemiology:</a></li><li><a href=#pathogenesis-1>Pathogenesis:</a></li><li><a href=#common-tumors>Common Tumors:</a></li></ol></li><li><a href=#hypercalcemia-osteolytic-bone-lesions>Hypercalcemia: Osteolytic Bone Lesions</a><ol><li><a href=#epidemiology-2>Epidemiology:</a></li><li><a href=#pathogenesis-2>Pathogenesis:</a></li><li><a href=#common-tumors-1>Common Tumors:</a></li></ol></li><li><a href=#treatment>Treatment</a></li><li><a href=#osteoclast-inhibition-modern-cornerstone-of-tx-wivfs>Osteoclast inhibition: Modern cornerstone of tx w/IVFs</a><ol><li><a href=#bisphosphonates>Bisphosphonates:</a></li><li><a href=#rank-l-inhibitor>RANK-L inhibitor:</a></li><li><a href=#loop-diuretics>Loop diuretics:</a></li><li><a href=#calcitonin>Calcitonin:</a></li><li><a href=#hd>HD:</a></li></ol></li><li><a href=#hypercalcemia-treatments>Hypercalcemia Treatments</a></li><li><a href=#hypercalcemia-management>Hypercalcemia Management</a></li></ol></nav></details></aside><a href=#metabolic-emergencies><h1 id=metabolic-emergencies><span class=hanchor arialabel=Anchor># </span>METABOLIC EMERGENCIES</h1></a><a href=#tumor-lysis-syndrome-and-hypercalcemia><h3 id=tumor-lysis-syndrome-and-hypercalcemia><span class=hanchor arialabel=Anchor># </span>Tumor lysis Syndrome and Hypercalcemia</h3></a><a href=#æ—å”éœ†><h4 id=æ—å”éœ†><span class=hanchor arialabel=Anchor># </span>æ—å”éœ†</h4></a><a href=#tumor-lysis-syndrome><h1 id=tumor-lysis-syndrome><span class=hanchor arialabel=Anchor># </span>TUMOR Lysis syndrome</h1></a><a href=#definition><h2 id=definition><span class=hanchor arialabel=Anchor># </span>Definition</h2></a><p>TLS is an oncologic emergency caused by electrolyte abnormalities</p><ul><li>a/w spontaneous and/or tx-induced cell death that can be potentially fatal.</li><li>There are 2 main classifications,<ul><li>lab</li><li>clinical</li></ul></li></ul><a href=#4-key-electrolyte-abnormalities-2-to-excessive-tumorcell-lysis><h2 id=4-key-electrolyte-abnormalities-2-to-excessive-tumorcell-lysis><span class=hanchor arialabel=Anchor># </span>4 key electrolyte abnormalities 2Â° to excessive tumor/cell lysis:</h2></a><ol><li>Hyperkalemia</li><li>Hyperphosphatemia</li><li>Hypocalcemia</li><li>Hyperuricemia (2Â° to catabolism of nucleic acids)</li></ol><a href=#presentation><h2 id=presentation><span class=hanchor arialabel=Anchor># </span>Presentation</h2></a><p>ä¸Šåä¸‹ç€‰ã€ä¸å°¿ä¸ä¾¿ã€ç¥ç¶“å­¸</p><ul><li>nausea</li><li>vomiting</li><li>diarrhea</li><li>constipation</li><li>oliguria/low UOP, wt gain, ARF,</li><li>weakness cramps, seizures, tetany, or dysrhythmias</li></ul><a href=#cairobishop-classification-system-for-tls-br-j-haematol-20041273><h2 id=cairobishop-classification-system-for-tls-br-j-haematol-20041273><span class=hanchor arialabel=Anchor># </span>Cairoâ€“Bishop Classification System for TLS (Br J Haematol 2004;127:3)</h2></a><a href=#lab-tls><h3 id=lab-tls><span class=hanchor arialabel=Anchor># </span>Lab TLS:</h3></a><ul><li>Abnormality in â‰¥2 w/in <code>3 d</code> before or <code>7 d</code> after the initiation of cytotoxic Rx<ul><li><code>UA</code> >8 mg/dL or 25% increase from baseline</li><li><code>Potassium</code> >6 mEq/L or 25% increase from baseline</li><li><code>Phosphate</code> >4.5 mg/dL or 25% increase from baseline</li><li><code>Ca</code> &lt;7 mg/dL or 25% decrease from baseline</li></ul></li></ul><hr><a href=#clinical-tls-1-lab-tls-marker-plus-1-clinical-abnormalities><h3 id=clinical-tls-1-lab-tls-marker-plus-1-clinical-abnormalities><span class=hanchor arialabel=Anchor># </span>Clinical TLS: â‰¥1 lab TLS marker plus â‰¥1 clinical abnormalities</h3></a><ul><li>Increased serum Cr (â‰¥1.5Ã— ULN)</li><li>Cardiac dysrhythmia</li><li>Seizure</li></ul><a href=#a-severity-grading-system-for-tls><h2 id=a-severity-grading-system-for-tls><span class=hanchor arialabel=Anchor># </span>A severity grading system for TLS</h2></a><p>has been established (<code>on a scale of 0â€“5</code>) based on the degree of Cr increase, presence & severity of cardiac dysrhythmia, & the presence & severity of seizures</p><p><img src=https://i.imgur.com/X0vk5vt.png width=auto alt=" h:350"></p><a href=#common-malignancies-associated-with-a-high-risk-of-developing-tls-in-adult-patients><h2 id=common-malignancies-associated-with-a-high-risk-of-developing-tls-in-adult-patients><span class=hanchor arialabel=Anchor># </span>Common Malignancies Associated with a High Risk of Developing TLS in Adult Patients</h2></a><ul><li>Acute leukemias (AML, ALL) w/large leukemic phase (>25â€“50K WBC)</li><li>High-grade lymphomas such as<ul><li>Burkitt lymphoma</li><li>DLBCL<ul><li>(of note, indolent lymphomas rarely cause TLS unless a large leukemic phase is present)</li></ul></li></ul></li></ul><a href=#certain-targeted-therapies-have-a-higher-risk-of-tls-in-cll-or-indolent-nhl><h2 id=certain-targeted-therapies-have-a-higher-risk-of-tls-in-cll-or-indolent-nhl><span class=hanchor arialabel=Anchor># </span>Certain targeted therapies have a higher risk of TLS in CLL or indolent NHL:</h2></a><a href=#venetoclax-especially-w><h3 id=venetoclax-especially-w><span class=hanchor arialabel=Anchor># </span>Venetoclax, especially w/</h3></a><ul><li>CYP3A (grapefruit juice)</li><li>P-gp inhibitors (amiodarone, clarithromycin, cyclosporine, diltiazem, erythromycin, ketoconazole, itraconazole, propafenone, quinidine, and verapamil.)</li></ul><a href=#obinutuzumab-no-large-tls-risk-w-follicular-lymphoma><h3 id=obinutuzumab-no-large-tls-risk-w-follicular-lymphoma><span class=hanchor arialabel=Anchor># </span>Obinutuzumab, no large TLS risk w/ follicular lymphoma</h3></a><a href=#risk-factors><h2 id=risk-factors><span class=hanchor arialabel=Anchor># </span>Risk Factors</h2></a><blockquote><p>(Br J Haematol 2010;149:578; N Engl J Med 2011;364:1844)</p></blockquote><a href=#disease-characteristics-aw-tls-risk><h3 id=disease-characteristics-aw-tls-risk><span class=hanchor arialabel=Anchor># </span>disease characteristics a/w TLS risk:</h3></a><ul><li>Rapidly progressive</li><li>chemosensitive</li><li>myelo- or lymphoproliferative disease, especially w/large leukemic phase (>25â€“50K WBC),</li><li>bulky disease (>10 cm in diameter),</li><li>extensive organ/marrow infiltration.</li></ul><hr><a href=#pt-characteristics-aw-tls-risk><h3 id=pt-characteristics-aw-tls-risk><span class=hanchor arialabel=Anchor># </span>Pt characteristics a/w TLS risk:</h3></a><ul><li>Baseline impaired renal function,<ul><li>oliguria, exposure to nephrotoxins, hyperuricemia</li></ul></li><li>Volume depletion/inadequate hydration, acidic urine</li></ul><a href=#monitoring><h2 id=monitoring><span class=hanchor arialabel=Anchor># </span>Monitoring</h2></a><p>UOP with advice goal of â‰¥100 mL/h</p><a href=#telemetry><h3 id=telemetry><span class=hanchor arialabel=Anchor># </span>Telemetry</h3></a><a href=#labs><h3 id=labs><span class=hanchor arialabel=Anchor># </span>Labs:</h3></a><p>BMP, UA, phosphate, Ca, & LDH</p><a href=#high-risk-pts><h3 id=high-risk-pts><span class=hanchor arialabel=Anchor># </span>High-risk pts</h3></a><p>could be monitored in ICU w/frequent labs</p><a href=#intermediate--or-low-risk-pts><h3 id=intermediate--or-low-risk-pts><span class=hanchor arialabel=Anchor># </span>Intermediate- or low-risk pts</h3></a><p>require lab monitoring over 8â€“12 h & daily, respectively</p><a href=#prophylaxis><h2 id=prophylaxis><span class=hanchor arialabel=Anchor># </span>Prophylaxis</h2></a><blockquote><p>(DeVita, Hellman, and Rosenbergâ€™s Cancer: Principles and Practice of Oncology. 10th ed. Lippincott Williams and Wilkins, 2015; Br J Haematol 2011;154:3)</p></blockquote><ul><li>IV hydration: Crystalloid solution (eg, NS) at 2â€“3 L/m2 per d, Â± diuretics</li><li>Allopurinol and/or rasburicase Rx (rasburicase [3â€“6 mg IV] in high-risk pts only), 1-time dosing + allopurinol vs. daily dosing.<ul><li>å–®æ¬¡6mgè¶³çŸ£</li><li>NB: Febuxostat has no established role in TLS PPx</li></ul></li><li>Urinary alkalinization no longer considered standard, not needed w/rasburicase</li></ul><a href=#management><h1 id=management><span class=hanchor arialabel=Anchor># </span>Management</h1></a><a href=#hyperkalemia><h2 id=hyperkalemia><span class=hanchor arialabel=Anchor># </span>Hyperkalemia:</h2></a><a href=#clinical-ss><h3 id=clinical-ss><span class=hanchor arialabel=Anchor># </span>Clinical S/S:</h3></a><ul><li>Asymptomatic</li><li>cardiac dysrhythmia and/or ECG changes<ul><li>(peaked T waves > PR seg prolong > p waves disappear > QRS prolonged > sine wave > asystole),</li></ul></li><li>muscle cramps, paresthesias</li><li>N/V, diarrhea</li></ul><hr><a href=#tx><h3 id=tx><span class=hanchor arialabel=Anchor># </span>Tx:</h3></a><a href=#mod--asx-6-mmoll><h4 id=mod--asx-6-mmoll><span class=hanchor arialabel=Anchor># </span>Mod. & asx, >6 mmol/L:</h4></a><ul><li>Cation exchange resins (Na polystyrene sulfonate/Kayexalate),</li><li>avoid IV & oral potassium,</li><li>stop meds (ACEi/ARBs/K+ sparing diuretics/NSAIDs, etc)</li></ul><hr><a href=#sev-7-mmoll-andor-symptomatic><h4 id=sev-7-mmoll-andor-symptomatic><span class=hanchor arialabel=Anchor># </span>Sev. (>7 mmol/L) and/or symptomatic:</h4></a><p>As above +</p><ul><li>Ca gluconate 1â€“2 g <code>æœ¬é™¢400mgä¸€æ”¯</code> : <code>4æ”¯</code> for life-threatening arrhythmias q5min prn,</li><li>regular insulin (5â€“10 U IV) + D50 (25 g of glucose) IV,</li><li>Na bicarb (50â€“100 mEq) <code>æœ¬é™¢16.6mEq/æ”¯</code> : <code>4æ”¯</code></li><li>loop diuretics</li><li>inhaled Î²-agonists (albuterol in higher doses 10â€“20 mg) <code>æœ¬é™¢5mg/æ”¯</code> :<code>2åˆ°4æ”¯</code></li><li>in sev./refractory cases: hemodialysis.</li></ul><a href=#hyperphosphatemia><h2 id=hyperphosphatemia><span class=hanchor arialabel=Anchor># </span>Hyperphosphatemia:</h2></a><a href=#clinical-ss-1><h4 id=clinical-ss-1><span class=hanchor arialabel=Anchor># </span>Clinical s/s:</h4></a><ul><li>Asymptomatic,</li><li>acute renal failure,</li><li>2Â° hypocalcemia (phosCa product >70),</li></ul><p>NB: Hyperphosphatemia in the presence of hypercalcemia imposes a high risk of metastatic calcification</p><hr><a href=#tx-1><h4 id=tx-1><span class=hanchor arialabel=Anchor># </span>Tx:</h4></a><ul><li>Exogenous sources of phosphate (enteral/parenteral nutrition, medications) should be reduced or eliminated.</li><li>PO phosphate binders<ul><li>calcium carbonate, calcium acetate,</li><li>sevelamer carbonate, lanthanum carbonate<ul><li>in pts with hypercalcemia;</li></ul></li></ul></li><li>in sev./refractory cases, hemodialysis may be beneficial</li></ul><a href=#hypocalcemia><h2 id=hypocalcemia><span class=hanchor arialabel=Anchor># </span>Hypocalcemia:</h2></a><a href=#clinical-ss-2><h3 id=clinical-ss-2><span class=hanchor arialabel=Anchor># </span>Clinical s/s:</h3></a><ul><li>excitation of nerve & muscle cells,<ul><li>causing neuromuscular irritability/spasm (eg, tetany, paresthesias, muscle twitching/cramping, laryngospasm/bronchospasm)</li><li>cardiac dysfunction (eg, dysrhythmia, HF),</li><li>mental status changes (eg, confusion, delirium, & hallucinations)</li><li>potential seizures, sudden death</li></ul></li></ul><hr><a href=#tx-2><h4 id=tx-2><span class=hanchor arialabel=Anchor># </span>Tx:</h4></a><ul><li>Confirm Ca2+, ionized Ca2+, albumin, PTH, vitamin D3, & Mg levels, & BMP</li><li>Correct hyperphosphatemia & in symptomatic cases give IV Ca gluconate (preferred to Ca chloride), 10â€“15 mg of calcium per kilogram body wt in 1 L of D5W & infused over 4â€“6 h, w/goal serum calcium level 7â€“8.5 mg/dL</li></ul><a href=#hyperuricemia><h2 id=hyperuricemia><span class=hanchor arialabel=Anchor># </span>Hyperuricemia:</h2></a><ul><li>Clinical s/s:
Asymptomatic, ARF</li></ul><a href=#tx-3><h4 id=tx-3><span class=hanchor arialabel=Anchor># </span>Tx:</h4></a><ul><li>Allopurinol vs. rasburicase, hemodialysis reserved for sev/refractory cases</li><li>No role for febuxostat at this time</li></ul><a href=#allopurinol-vs-rasburicase><h2 id=allopurinol-vs-rasburicase><span class=hanchor arialabel=Anchor># </span>Allopurinol vs. Rasburicase</h2></a><p><img src=https://i.imgur.com/D2pWjyB.png width=auto alt=" h:500"></p><a href=#hypercalcemia><h1 id=hypercalcemia><span class=hanchor arialabel=Anchor># </span>Hypercalcemia</h1></a><a href=#hypercalcemia-overview><h2 id=hypercalcemia-overview><span class=hanchor arialabel=Anchor># </span>Hypercalcemia: Overview</h2></a><a href=#epidemiology><h3 id=epidemiology><span class=hanchor arialabel=Anchor># </span>Epidemiology:</h3></a><p>~10â€“30% of all pts w/malignancy</p><a href=#definition-1><h3 id=definition-1><span class=hanchor arialabel=Anchor># </span>Definition:</h3></a><ul><li>Normal values: 9â€“10.5 mg/dL,</li><li>mild = elevated but &lt;12;</li><li>mod. = 12â€“14;</li><li>sev. >14</li></ul><hr><a href=#ä¸€èˆ¬æƒ…æ³éƒ½æ˜¯æŠ½caalb><h3 id=ä¸€èˆ¬æƒ…æ³éƒ½æ˜¯æŠ½caalb><span class=hanchor arialabel=Anchor># </span>ä¸€èˆ¬æƒ…æ³éƒ½æ˜¯æŠ½Ca+Alb:</h3></a><p>Corrected [Ca] = Measured total [Ca] + (0.8 x (4.0 - [Alb]))
(é€™å€‹å–®ä½æ˜¯mg/dLï¼Œé€Ÿè¨˜ï¼šå¦‚æœAlbuminæ˜¯2.5ï¼Œè¦åŠ 2)</p><a href=#freecaä¸€èˆ¬ä¾†èªªæ˜¯ä¸€èˆ¬caçš„40-50><h3 id=freecaä¸€èˆ¬ä¾†èªªæ˜¯ä¸€èˆ¬caçš„40-50><span class=hanchor arialabel=Anchor># </span>FreeCaï¼Œä¸€èˆ¬ä¾†èªªæ˜¯ä¸€èˆ¬Caçš„40-50%</h3></a><p>å’Œä¿¡FreeCaå–®ä½æ˜¯mg/dLï¼Œæ‰€ä»¥ç›´æ¥ä¹˜èµ·ä¾†æ²’å•é¡Œï¼Œä½†æ˜¯å¦‚æœä»Šå¤©æ˜¯åœ¨åŒ—æ¦®çš„è©±ï¼Œå–®ä½æ˜¯mmol/Lï¼Œå°±æ˜¯è¦é™¤åˆ†å­é‡ï¼Œå°±æ˜¯è¦å†é™¤å››</p><a href=#tldr><h3 id=tldr><span class=hanchor arialabel=Anchor># </span>TLDR</h3></a><p>å¦‚æœCa = 8 mg/dL Albumin = 4
å‰‡ iCa = 4 mg/dL, 1mmol/L</p><blockquote><p>Ca (mmol/L) = Ca measured (mmol/L) + 0.02*[40 - albumin (g/L]) (note: may be inaccurate in renal dx/ESRD pts)</p></blockquote><hr><a href=#pathogenesis><h3 id=pathogenesis><span class=hanchor arialabel=Anchor># </span>Pathogenesis:</h3></a><ol><li>Humorally mediated via PTHrP (secreted from tumor cells)</li><li>osteolytic focal bone destruction from paracrine factors,</li><li>rarely ectopic calcitriol (lymphoma), 1,25-vit D or PTH production</li></ol><hr><p><img src=https://i.imgur.com/MKUEY7f.jpg width=auto alt="bg h:700"></p><hr><a href=#symptoms><h3 id=symptoms><span class=hanchor arialabel=Anchor># </span>Symptoms:</h3></a><ul><li>Polyuria/polydipsia</li><li>intravascular volume depletion,</li><li>AKI</li><li>lethargy, AMS, rarely coma/seizures</li><li>N/V</li><li>ECG changes (â†“ QTc)</li><li>â†‘ risk of digoxin tox</li></ul><a href=#workup><h2 id=workup><span class=hanchor arialabel=Anchor># </span>Workup:</h2></a><a href=#hp><h3 id=hp><span class=hanchor arialabel=Anchor># </span>H/P:</h3></a><ul><li>Bone pain, meds/diet (thiazides/Li, vitamin supplements, TPN volume status, FHH)</li></ul><a href=#labs-1><h3 id=labs-1><span class=hanchor arialabel=Anchor># </span>Labs:</h3></a><ul><li>CMP (Ca, Cr, alb, phos), iCa, iPTH,</li><li>if unclear source â†’ PTHrP & vit D (1,25 & 25-OH),</li><li>still unclear â†’ SPEP/UPEP/FLC,</li><li>still unclear â†’ CXR/vit A/endocrine workup</li></ul><a href=#hypercalcemia-humoral-mechanisms><h2 id=hypercalcemia-humoral-mechanisms><span class=hanchor arialabel=Anchor># </span>Hypercalcemia: Humoral Mechanisms</h2></a><a href=#epidemiology-1><h3 id=epidemiology-1><span class=hanchor arialabel=Anchor># </span>Epidemiology:</h3></a><ul><li>~80% of all hyperCa of malignancy</li></ul><a href=#pathogenesis-1><h3 id=pathogenesis-1><span class=hanchor arialabel=Anchor># </span>Pathogenesis:</h3></a><ul><li>PTHrP (shares same amino acid terminus as PTH)</li><li>less commonly calcitriol are secreted by tumor â†’ â†‘ bone turnover & â†‘ renal Ca reabsorption.</li></ul><hr><a href=#common-tumors><h3 id=common-tumors><span class=hanchor arialabel=Anchor># </span>Common Tumors:</h3></a><ul><li>SCC of lung</li><li>head/neck</li><li>renal</li><li>bladder</li><li>NHL</li><li>leukemias</li><li>HL (calcitriol)</li></ul><a href=#hypercalcemia-osteolytic-bone-lesions><h2 id=hypercalcemia-osteolytic-bone-lesions><span class=hanchor arialabel=Anchor># </span>Hypercalcemia: Osteolytic Bone Lesions</h2></a><a href=#epidemiology-2><h3 id=epidemiology-2><span class=hanchor arialabel=Anchor># </span>Epidemiology:</h3></a><p>~20% of all hyperCa of malignancy</p><a href=#pathogenesis-2><h3 id=pathogenesis-2><span class=hanchor arialabel=Anchor># </span>Pathogenesis:</h3></a><p>Tumor mets to bone â†’ express PTHrP locally (paracrine) â†’ activate osteoclasts via RANKLâ€“RANK interaction â†’ bone resorption â†’ â†‘Ca</p><a href=#common-tumors-1><h3 id=common-tumors-1><span class=hanchor arialabel=Anchor># </span>Common Tumors:</h3></a><p>Breast, lung, MM, renal, less likely prostate (osteoblastic)</p><a href=#treatment><h2 id=treatment><span class=hanchor arialabel=Anchor># </span>Treatment</h2></a><ul><li>Medication, supplement, & diet review; stop offending agents, if possible</li><li>Tx underlying malignancy, only way to effectively treat, all other tx are temporizing</li><li>IVFs are essential in tx â†’ rapidly correct hypovolemia & AKI â†’ promote calciuresis</li></ul><a href=#osteoclast-inhibition-modern-cornerstone-of-tx-wivfs><h2 id=osteoclast-inhibition-modern-cornerstone-of-tx-wivfs><span class=hanchor arialabel=Anchor># </span>Osteoclast inhibition: Modern cornerstone of tx w/IVFs</h2></a><a href=#bisphosphonates><h3 id=bisphosphonates><span class=hanchor arialabel=Anchor># </span>Bisphosphonates:</h3></a><p>Pamidronate (60â€“90 mg IV) & zoledronic acid (4 mg IV), which may be superior to pamidronate (JCO 2001;19:558), either acceptable; ZA â†‘ risk of AKI/ATN. Both â†‘ risk of â†“Ca.</p><a href=#rank-l-inhibitor><h3 id=rank-l-inhibitor><span class=hanchor arialabel=Anchor># </span>RANK-L inhibitor:</h3></a><p>Denosumab approved for hyperCa of malignancy refractory to bisphosphonates, â†‘ risk of hypoCa, especially if recent bisphosphonate use or prostate CA w/blastic lesions</p><hr><a href=#loop-diuretics><h3 id=loop-diuretics><span class=hanchor arialabel=Anchor># </span>Loop diuretics:</h3></a><p>Unnecessary unless concern for volume overload; no data support utility (Ann Int Med 2008;149:259).</p><a href=#calcitonin><h3 id=calcitonin><span class=hanchor arialabel=Anchor># </span>Calcitonin:</h3></a><p>Rapid, temporary â†“ Ca, monitor for hypoCa, HSR, & tachyphylaxis (>48 h)</p><a href=#hd><h3 id=hd><span class=hanchor arialabel=Anchor># </span>HD:</h3></a><p>If all above fail â†’ AKI progresses â†’ sev. hypervolemia</p><a href=#hypercalcemia-treatments><h2 id=hypercalcemia-treatments><span class=hanchor arialabel=Anchor># </span>Hypercalcemia Treatments</h2></a><p><img src=https://i.imgur.com/PjRNj5b.png width=auto alt=" h:500"></p><a href=#hypercalcemia-management><h2 id=hypercalcemia-management><span class=hanchor arialabel=Anchor># </span>Hypercalcemia Management</h2></a><p><img src=https://i.imgur.com/zIe14W9.png width=auto alt=" h:300"></p></article><hr><div class=page-end id=footer><div class=backlinks-container><h3>â†©ï¸ åå‘é€£çµ</h3><ul class=backlinks><li>ğŸ¤­æ²’æœ‰æ‰¾åˆ°åå‘é€£çµ</li></ul></div><div><script async src=https://cdn.jsdelivr.net/npm/d3@6.7.0/dist/d3.min.js integrity="sha256-+7jaYCp29O1JusNWHaYtgUn6EhuP0VaFuswhNV06MyI=" crossorigin=anonymous></script><h3>ğŸ¤¯äº’å‹•åœ–</h3><div id=graph-container></div><style>:root{--g-node:var(--secondary);--g-node-active:var(--primary);--g-node-inactive:var(--visited);--g-link:var(--outlinegray);--g-link-active:#5a7282}</style><script src=https://www.physician.tw/js/graph.2d9e48dbe7ea47c0ef1c58296ce14448.js></script></div></div><div><div id=disqus_thread></div><script type=application/javascript>window.disqus_config=function(){},function(){if(["localhost","127.0.0.1"].indexOf(window.location.hostname)!=-1){document.getElementById("disqus_thread").innerHTML="Disqus comments not available by default when the website is previewed locally.";return}var t=document,e=t.createElement("script");e.async=!0,e.src="//physician.disqus.com/embed.js",e.setAttribute("data-timestamp",+new Date),(t.head||t.body).appendChild(e)}()</script><noscript>Please enable JavaScript to view the <a href=https://disqus.com/?ref_noscript>comments powered by Disqus.</a></noscript><a href=https://disqus.com class=dsq-brlink>comments powered by <span class=logo-disqus>Disqus</span></a></div><div id=contact_buttons><footer><p>æœ¬ç¶²ç«™æ˜¯ç”± Hsieh-Ting Lin ä»¥â¤ï¸ ç”¨ <a href=https://github.com/jackyzha0/quartz>Quartz</a>é€™å€‹é…·æ±è¥¿ç¨®å‡ºä¾†ğŸª´ , Â© 2023</p><p><a href=https://www.buymeacoffee.com/htl.lizard><img src=https://cdn.buymeacoffee.com/buttons/v2/default-yellow.png width=200></a></p><ul><li><a href=https://www.physician.tw/>ğŸ é¦–é </a></li><li><a href=https://www.facebook.com/Tim.H.Lin>Facebook</a></li><li><a href=https://twitter.com/htlin222>Twitter</a></li><li><a href=https://github.com/htlin222>GitHub</a></li><li><a href=https://htlin.site>Blog</a></li><li><a href=https://medium.com/@hsieh-ting-lin>Medium</a></li></ul></footer></div></div></body></html>